Copyright
©The Author(s) 2021.
World J Clin Cases. Nov 6, 2021; 9(31): 9440-9451
Published online Nov 6, 2021. doi: 10.12998/wjcc.v9.i31.9440
Published online Nov 6, 2021. doi: 10.12998/wjcc.v9.i31.9440
Table 1 Clinical characteristics of the patients
Derivation cohort (n = 796) | Validation cohort (n = 448) | ||||||
Favorable outcome | Unfavorable outcome | P | Favorable outcome | Unfavorable outcome | P | ||
n = 750 | n = 46 | n = 423 | n = 25 | ||||
Age, median (IQR) | 63 (52, 71) | 64.5 (59, 72) | 0.26 | 63 (52, 70) | 69 (62, 75) | 0.03 | |
Sex | 0.87 | 0.01 | |||||
Female | 217 (28.9%) | 14 (30.4%) | 132 (31.2%) | 2 (8.0%) | |||
Male | 533 (71.1%) | 32 (69.6%) | 291 (68.8%) | 23 (92.0%) | |||
Hypertension | 469 (62.5%) | 26 (56.5%) | 0.44 | 261 (61.7%) | 17 (68.0%) | 0.67 | |
Diabetes | 229 (30.5%) | 18 (39.1%) | 0.25 | 99 (23.4%) | 3 (12.0%) | 0.23 | |
FPG, median (IQR) | 5.6 (5, 7.33) | 5.915 (4.66, 7.22) | 0.67 | 5.41 (4.89, 6.65) | 4.85 (4.57, 5.45) | 0.02 | |
Cardiopathy | 59 (7.9%) | 7 (15.2%) | 0.09 | 40 (9.5%) | 7 (28.0%) | < 0.01 | |
Smoking | 188 (25.1%) | 15 (32.6%) | 0.29 | 100 (23.6%) | 11 (44.0%) | 0.03 | |
UA, median (IQR) | 298 (243, 359) | 280 (179, 332) | 0.04 | 306 (238, 364) | 298 (179, 354) | 0.61 | |
UN, median (IQR) | 5.3 (4.48, 6.54) | 4.82 (3.81, 6.36) | 0.11 | 5.5 (4.38, 6.98) | 5.8 (3.81, 6.3) | 0.34 | |
Hcy, median (IQR) | 13.96 (11.07, 19.03) | 13.56 (10.01, 18.4) | 0.33 | 14.04 (10.53, 17.6) | 16.43 (10.01, 26.82) | 0.18 | |
CRP, median (IQR) | 1.415 (0.51, 6.13) | 1.325 (0.6, 3.9) | 0.58 | 1.62 (0.56, 4.7) | 1.56 (0.89, 3.57) | 0.94 | |
TC, median (IQR) | 4.435 (3.84, 5.2) | 4.89 (3.96, 5.36) | 0.08 | 4.4 (3.89, 5.04) | 5.02 (3.49, 5.75) | 0.16 | |
TG, median (IQR) | 1.52 (1.08, 2.12) | 1.72 (1.32, 2.45) | 0.09 | 1.47 (1.06, 2.05) | 1.38 (0.89, 1.86) | 0.46 | |
LDLC, median (IQR) | 2.615 (2.04, 3.25) | 3.15 (2.34, 3.52) | 0.03 | 2.57 (2.14, 3.19) | 3.26 (2.3, 3.71) | 0.04 | |
Stable plaques | 288 (38.4%) | 18 (39.1%) | 1.00 | 147 (34.8%) | 6 (24.0%) | 0.39 | |
Vulnerable plaque | 400 (53.3%) | 21 (45.7%) | 0.36 | 217 (51.3%) | 10 (40.0%) | 0.31 | |
Alcohol drinking | 256 (34.1%) | 18 (39.1%) | 0.52 | 131 (31.0%) | 11 (44.0%) | 0.19 | |
HDLC, median (IQR) | 1.1 (0.94, 1.36) | 1.145 (0.9, 1.28) | 0.56 | 1.12 (0.95, 1.37) | 1.14 (1.05, 1.46) | 0.47 | |
APOA, median (IQR) | 1.35 (1.21, 1.55) | 1.415 (1.19, 1.58) | 0.56 | 1.35 (1.22, 1.54) | 1.46 (1.19, 1.53) | 0.47 | |
APOB, median (IQR) | 0.925 (0.73, 1.09) | 1.1 (0.84, 1.22) | < 0.01 | 0.91 (0.73, 1.08) | 1 (0.75, 1.16) | 0.46 | |
LP(a), median (IQR) | 208.5 (112, 340) | 173.5 (124, 371) | 0.78 | 187 (106, 329) | 151 (129, 371) | 0.99 | |
Cr, median (IQR) | 55.65 (14.72, 72.1) | 65.1 (48.6, 80) | < 0.01 | 55.9 (14.7, 69.8) | 70.2 (48.8, 78.3) | 0.01 | |
STBL, median (IQR) | 17.985 (11.7, 58) | 15.11 (11.5, 19.03) | 0.02 | 17.23 (11.7, 60.2) | 14.86 (11.5, 17.3) | 0.19 | |
Ferritin, median (IQR) | 220.85 (136.59, 324.3) | 255.57 (218.1, 426.1) | < 0.01 | 207.18 (131.2, 318.78) | 252.2 (191.83, 350.6) | 0.09 | |
GHb, median (IQR) | 6.66 (5.82, 7.94) | 7.18 (6.3, 9.09) | 0.14 | 5.82 (4.68, 7.4) | 5.91 (4.53, 6.72) | 0.33 | |
SBP, median (IQR) | 142 (130, 158) | 147 (139, 163) | 0.08 | 140 (129, 155) | 140 (120, 154) | 0.49 | |
DBP, median (IQR) | 82 (75, 92) | 84.5 (80, 90) | 0.48 | 82 (75, 91) | 89 (81, 90) | 0.28 |
Table 2 Univariate and multivariate logistic regression analyses for outcomes
Univariate analysis | Multivariate analysis | |||||
OR | 95%CI | P | OR | 95%CI | P | |
Age | 1.027 | 0.994-1.060 | 0.109 | 1.014 | 0.987-1.043 | 0.315 |
Sex | 0.853 | 0.364-1.998 | 0.714 | – | ||
Hypertension | 0.633 | 0.311-1.290 | 0.208 | – | ||
Diabetes | 1.550 | 0.668-3.597 | 0.308 | – | ||
FPG | 0.896 | 0.741-1.084 | 0.260 | – | ||
Cardiopathy | 2.087 | 0.803-5.422 | 0.131 | 2.021 | 0.816-5.003 | 0.128 |
Smoking | 1.375 | 0.588-3.217 | 0.462 | – | ||
Uric acid | 0.997 | 0.994-1.001 | 0.179 | 0.997 | 0.993-0.999 | 0.038 |
UN | 0.877 | 0.715-1.076 | 0.207 | – | ||
Homocysteine | 0.994 | 0.958-1.031 | 0.751 | – | ||
CRP | 0.995 | 0.972-1.018 | 0.642 | – | ||
TC | 0.997 | 0.968-1.027 | 0.833 | – | ||
TG | 1.000 | 0.896-1.116 | 0.996 | – | ||
LDLC | 1.037 | 0.878-1.225 | 0.665 | – | ||
Vulnerable plaque | 0.620 | 0.244-1.576 | 0.315 | – | ||
Stable plaque | 0.634 | 0.250-1.606 | 0.337 | – | ||
Alcohol drinking | 0.983 | 0.443-2.181 | 0.967 | – | ||
HDLC | 0.745 | 0.245-2.265 | 0.604 | – | ||
APOA | 1.061 | 0.646-1.742 | 0.815 | – | ||
APOB | 0.981 | 0.750-1.283 | 0.891 | – | ||
LP a | 1.000 | 0.999-1.001 | 0.929 | – | ||
Cr | 1.001 | 0.992-1.010 | 0.851 | – | ||
STBL | 0.975 | 0.956-0.995 | 0.013 | 0.973 | 0.956-0.990 | 0.002 |
Ferritin | 1.003 | 1.001-1.005 | 0.001 | 1.004 | 1.002-1.006 | < 0.001 |
GHb | 1.067 | 0.843-1.352 | 0.588 | – | ||
SBP | 1.012 | 0.995-1.031 | 0.169 | 1.012 | 0.999-1.025 | 0.071 |
DBP | 1.007 | 0.978-1.037 | 0.633 | – |
Table 3 Summary of the confusion matrix for the training dataset and testing dataset
Actual outcome | Actual outcome | ||||
No relapse during hospitalization | Relapse during hospitalization | No relapse during hospitalization | Relapse during hospitalization | ||
Predicted outcome | No relapse during hospitalization | 750 | 45 | 423 | 25 |
Relapse during hospitalization | 0 | 1 | 0 | 0 |
- Citation: Yu XF, Yin WW, Huang CJ, Yuan X, Xia Y, Zhang W, Zhou X, Sun ZW. Risk factors for relapse and nomogram for relapse probability prediction in patients with minor ischemic stroke. World J Clin Cases 2021; 9(31): 9440-9451
- URL: https://www.wjgnet.com/2307-8960/full/v9/i31/9440.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i31.9440